S. 124 - Preserve Access to Affordable Generics Act
- Sponsor:
- Amy Klobuchar
- Summary:
- A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. (by CRS)
- Status:
- The bill has been referred to committee.
Preserve Access to Affordable Generics Act
S. 124 — 115th Congress (2017–2018)
- Summary
- A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. (by CRS)
- Learn More
- At OpenCongress
- Title
- A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.
- Other Titles
- Preserve Access to Affordable Generics Act
- Preserve Access to Affordable Generics Act
- Preserve Access to Affordable Generics Act
- Sponsor
- Amy Klobuchar
- Co-Sponsors
- Subjects
- Health
- Administrative law and regulatory procedures
- Civil actions and liability
- Competition and antitrust
- Contracts and agency
- Federal Trade Commission (FTC)
- Intellectual property
- Judicial review and appeals
- Marketing and advertising
- Prescription drugs
- Related Bills
- Major Actions
Introduced 1/12/2017 Referred to Committee - Bill History
-
There have been no votes on this bill.
Action Date Description Introduced 1/12/2017 1/12/2017 Introduced in Senate 1/12/2017 Read twice and referred to the Committee on the Judiciary. Number Sponsor Date Offered Status
- chart
- table
Total contributions given to Senators from Elderly issues/Social Security, which…
support this bill
Elderly issues/Social Security | $259,310 |
$259,310 |
Contributions data source: OpenSecrets.org